In addition to the 5 neuromuscular and cardiac indications previously mentioned, Sarepta will have exclusive options on other potential targets. 1 The news comes following other major announcements from Sarepta regarding their DMD programs. Late last month, Sarepta announced plans to submit a biologic license application for SRP-9001, an investigative gene therapy for DMD, following positive efficacy and safety results reported several weeks earlier. However, it was also announced in June that one of Sarepta's other investigational DMD gene therapies, SRP-5051, was placed on clinical hold by the FDA related to a serious adverse event of hypomagnesemia that occurred in part B of the ongoing 2-part, phase 2 MOMENTUM clinical trial (NCT04004065). REFERENCES 1. Sarepta Therapeutics announces progress on the MyoAAV program and exclusive licensing agreement with the broad institute for MyoAAV next-generation capsids for rare genetic diseases. News release.